hrp0094p2-332 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Evaluating Safety, Efficacy, and Pharmacokinetics of Weekly TransCon CNP in Children with Achondroplasia: Design of the ACcomplisH Trial

McDonnell Ciara , Irving Melita , Zarate Yuri , B. Hove Hanne , Hogler Wolfgang , Hoernschemeyer Daniel , Zhang Ying , Viuff Dorthe , Hartoft-Nielsen Marie-Louise , Beckert Michael , Savarirayan Ravi ,

Achondroplasia (ACH) is the most common form of dwarfism, occurring in 1: 20,000 births. ACH is caused by gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3) gene that interfere with endochondral ossification. Clinically significant morbidities are frequent in ACH; however, there are currently no approved therapies that target the underlying pathobiology. C-type natriuretic peptide (CNP) is an attractive target as it has the potential to inhi...

hrp0097fc10.1 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders | ESPE2023

Dasiglucagon safety in paediatric participants with CHI

Meissner Thomas , D. De León Diva , Thornton Paul , Zangen David , Mohnike Klaus , Andersen Marie , Bøge Eva , Birch Sune , Ivkovic Jelena , Banerjee Indi

Background: Congenital hyperinsulinism (CHI) is a rare disorder, which causes persistent and severe hypoglycaemia in infants and children. CHI can be treated with glucagon, but long-term use is challenging owing to its instability in aqueous solution. Dasiglucagon, a stable glucagon analogue designed for long-term use as a subcutaneous continuous infusion, is in clinical development. Here, we present dasiglucagon safety results in participants treated for up t...

hrp0097rfc9.1 | Diabetes and insulin 2 | ESPE2023

The association of dietary glycemic index and load with insulin sensitivity and secretion from early childhood to late adolescence: the QUALITY cohort

Cattrysse Pascaline , Harnois-Leblanc Soren , Sallah Drammeh Pa , Drapeau Vicky , A. Barnett Tracie , Mathieu Marie-Ève , Suissa Karine , Benedetti Andrea , Henderson Mélanie

Introduction: With the increasing prevalence of obesity, prediabetes and type 2 diabetes (T2D) in youth are on the rise. Prevention is paramount for these multifactorial diseases. Dietary interventions targeting a reduction of dietary glycemic index (GI) and glycemic load (GL) are potential strategies for improving insulin resistance. However, the association between GI and GL and T2D risk in children remains uncertain.Objectives...

hrp0097p1-31 | Diabetes and Insulin | ESPE2023

Metabolic trajectories during treatment of diabetic ketoacidosis described by breath analysis

Awchi Mo , Dev Singh Kapil , Bachmann-Brenner Sara , Burckhardt Marie-Anne , Hess Melanie , Zumsteg Urs , Zeng Jiafa , N. Datta Alexandre , Frey Urs , Szinnai Gabor , Sinues Pablo

Objective: This feasibility study aimed to investigate the anabolic effect of insulin on metabolites captured in exhaled breath during acute diabetic ketoacidosis (DKA) for a better pathophysiological understanding.Research Design and Methods: Children and adolescents with type 1 diabetes (T1D) with DKA (n=5) and without DKA (n=7) and children with epilepsy without ketogenic diet (n=18) were re...

hrp0097p1-509 | Growth and Syndromes | ESPE2023

Significant height response to growth hormone treatment in subjects with Wiedemann Steinert syndrome.

Le Potier Emma , Donzeau Aurélie , Rouleau Stephanie , Bouhours-Nouet Natacha , Levaillant Lucie , Peborde Marie , Poisson Audrey , Alcina Mailys , Coutant Regis

Background: Wiedemann Steinert Syndrome (WSS) is characterized by distinctive facial features (hypertelorism, thick eyebrows, long philtrum, broad nasal bridge), growth retardation, and intellectual disability of varying degrees. Affected individuals are often born small for their gestational age and have generalized hypertrichosis. Some have growth hormone deficiency, usually partial with normal pituitary MRI. The disease is caused by autosomal dominant varia...

hrp0097p1-388 | Thyroid | ESPE2023

Neutropenia in paediatric Graves disease patients occurs more often under Carbimazole than Methimazole

Schempp Vera , Nurcan Cebeci Ayse , Reinauer Christina , Woelfle Joachim , Dörr Helmuth-Günther , Roosen Marie-Thérèse , Gohlke Jonas , Gohlke Bettina

Introduction: Neutropenia is known as a rare adverse event of anti-thyroid drug treatment (ATD) but has also been reported as pre-treatment neutropenia in Graves’ disease (GD). Studies on paediatric patients are rare. To the best of our knowledge, there are no data comparing the effects of methimazole (MMI) and carbimazole (CBZ) treatment in children on the absolute neutrophil count (ANC).Methods: We analyzed retro...

hrp0098p2-16 | Adrenals and HPA Axis | ESPE2024

The challenge of diagnosis and management of micronodular adrenocortical disease in a 7-year old girl with cyclic cushing syndrome: a case report

Alice Manzardo Olimpia , Ritter Marie , Muehlschlegel Geeske , Hodde Franka , Van der Werf Natascha , Lichte Kai , F Hartmann Michaela , A Wudy Stefan , Kamrath Clemens

Background: We present the case of a 7-year old girl presenting with undulant ACTH independent Cushing syndrome (CS).Case presentation: The patient presented at a secondary care centre with hyperphagia, fatigue and 8 kg weight increase 4 weeks after an upper airway infection. The parents described a similar episode with spontaneous regression 12 months before. At physical examination she showed a cushingoid habitus with ...

hrp0098p2-321 | Late Breaking | ESPE2024

Lipid lowering therapy, LDL- and non-HDL-cholesterol in children and adolescents with type 1 diabetes: An analysis based on the DPV registry

Becker Marianne , Weiskorn Jantje , Kamrath Clemens , Hammersen Johanna , Bechtold-Dalla Pozza Susanna , Müller-Roßberg Elke , Holder Martin , Burckhardt Marie-Anne , Holl Reinhard

Background: Cardiovascular risk factors largely determine morbidity and mortality in people with type 1 diabetes (T1D). Hyperlipidemia, especially in pediatric patients, is often undertreated, although it can lead to premature atherosclerotic changes. While non-HDL-C (non-HDL-cholesterol) is an important risk factor for cardiovascular events in patients with diabetes, guidelines only define LDL-C treatment targets. According to current ISPAD guidelines, childr...

hrp0098p3-157 | Growth and Syndromes | ESPE2024

Radiographic features and response to growth hormone therapy for SHOX deficiency: A case series

Sugiura Aiko , Nakagawa Marie , Yamano Shio , Shioda Shogo , Honma Takehiro , Fukui Sadahiro , Tanimoto Eri , Ujita Nagisa , Miyagi Hazime , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: In patients with SHOX deficiency, radiographic abnormalities can vary, with some cases showing no deformities or only mild deformities, particularly in young children, while Madelung deformity is the most commonly observed radiographic feature. Growth hormone (GH) therapy for individuals with SHOX deficiency has been available in Japan since June 2023. This report summarizes a case series of SHOX deficiency diagnosed at a single institution, with a...

hrp0089fc9.2 | Pituitary, neuroendocrinology and Puberty 1 | ESPE2018

Contribution of Functionally Assessed GHRHR Mutations to Idiopathic Isolated Growth Hormone Deficiency in a Cohort of 312 Unrelated Patients

Cohen Enzo , Belkacem Sabrina , Fedala Soumeya , Collot Nathalie , Khallouf Eliane , Dastot Florence , Polak Michel , Duquesnoy Philippe , Brioude Frederic , Rose Sophie , Viot Geraldine , Soleyan Aude , Carel Jean-Claude , Sobrier Marie-Laure , Chanson Philippe , Gatelais Frederique , Heinrichs Claudine , Kaffel Noureddine , Coutant Regis , Erdeve Şenay Savaş , Aycan Zehra , Thalassinos Caroline , Lyonnet Stanislas , Şıklar Zeynep , Berberoglu Merih , Brachet Cecile , Amselem Serge , Legendre Marie

Purpose: Isolated growth hormone deficiency (IGHD) is a rare condition mainly caused by mutations in GH1. The aim of this study was to assess the contribution of GHRHR mutations to IGHD in a very large cohort of patients.Methods: All GHRHR coding exons and flanking intronic regions were sequenced in 312 unrelated patients with non-syndromic IGHD. Functional consequences of all newly identified missense variants were assessed <e...